Check out these 2 articles! This is exciting!!!
Read about the deal on CannabizECS Botanics has secured an exclusive licence from California-based breeding group Terphogz to manufacture and sell its medicinal cannabis range in Germany, Australia and New Zealand.
Under the eight-year deal, the range will launch in Germany under a B2B model and in Australia through a new, direct-to-consumer, channel. The most appropriate channel for New Zealand has yet to be determined.
Terphogz owns a genetic library known for creating some of the most sought-after strains in the industry, including the award-winning ‘The Original Z’.
ECS told the ASX the agreement leverages its cultivation capabilities, licensed GMP facilities and global reach – along with Terphogz genetics, product portfolio, and brand – “to provide patients access to genetics and products previously limited to Californian medical and recreational markets”.
Read on RMRIn a significant move for the cannabis community, ECS Botanics Holdings Ltd (ASX: ECS) has officially inked a licensing deal with the iconic Terphogz brand from California. This partnership, set to unfold over the next eight years, will see ECS granted exclusive rights to manufacture and supply a selection of Terphogz cannabis products across international cannabis markets in Germany, Australia, and New Zealand.
Terphogz, hailing from Mendocino County, California, has earned a legendary reputation in the cannabis breeding world, particularly known for its groundbreaking strain, “The Original Z” (Zkittlez). This strain and its offspring have garnered numerous awards, including multiple first-place trophies at prestigious competitions like The Emerald Cup. Beyond the awards, the strain has found itself at the heart of the candy movement as a parent for many now classic strains and a beloved flavor in its own right. These hall of fame genetics are now primed to reach international markets, providing patients with access to the distinctive flavors and effects that Terphogz is celebrated for.
ECS Botanics is strategically positioned to leverage this partnership. With a robust cultivation infrastructure and GMP-certified facilities, ECS is not only set to grow these sought-after genetics but also to distribute them through established networks in key markets. Germany, for instance, is projected to see its cannabis market soar to $7.4 billion by 2033. The Terphogz brand already holds a respected position there, making this an ideal launching pad for ECS’s expansion.
While the US continues to slow roll legalization across the states, international markets have made nationwide legalization movements allowing importing, exporting, and cross country commerce opportunities that Terphogz can now leverage alongside ECS.
Last edited by a moderator: